These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cardiac Fibrosis: The Fibroblast Awakens. Travers JG; Kamal FA; Robbins J; Yutzey KE; Blaxall BC Circ Res; 2016 Mar; 118(6):1021-40. PubMed ID: 26987915 [TBL] [Abstract][Full Text] [Related]
5. A primer on current progress in cardiac fibrosis. Al Hattab D; Czubryt MP Can J Physiol Pharmacol; 2017 Oct; 95(10):1091-1099. PubMed ID: 28273426 [TBL] [Abstract][Full Text] [Related]
6. Potential reduction of interstitial myocardial fibrosis with renal denervation. Doltra A; Messroghli D; Stawowy P; Hassel JH; Gebker R; Leppänen O; Gräfe M; Schneeweis C; Schnackenburg B; Fleck E; Kelle S J Am Heart Assoc; 2014 Dec; 3(6):e001353. PubMed ID: 25516438 [TBL] [Abstract][Full Text] [Related]
7. Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis. Teng G; Svystonyuk D; Mewhort HE; Turnbull JD; Belke DD; Duff HJ; Fedak PW Am J Physiol Heart Circ Physiol; 2015 Jun; 308(12):H1564-74. PubMed ID: 25862829 [TBL] [Abstract][Full Text] [Related]
8. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Chang SA; Kim YJ; Lee HW; Kim DH; Kim HK; Chang HJ; Sohn DW; Oh BH; Park YB Hypertension; 2009 Sep; 54(3):591-7. PubMed ID: 19564547 [TBL] [Abstract][Full Text] [Related]
10. Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. Schelbert EB; Sabbah HN; Butler J; Gheorghiade M Circ Cardiovasc Imaging; 2017 Jun; 10(6):. PubMed ID: 28512159 [TBL] [Abstract][Full Text] [Related]
11. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Bartha E; Solti I; Kereskai L; Lantos J; Plozer E; Magyar K; Szabados E; Kálai T; Hideg K; Halmosi R; Sumegi B; Toth K Cardiovasc Res; 2009 Aug; 83(3):501-10. PubMed ID: 19443425 [TBL] [Abstract][Full Text] [Related]
12. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. López B; González A; Querejeta R; Larman M; Rábago G; Díez J Hypertension; 2014 Mar; 63(3):483-9. PubMed ID: 24366078 [TBL] [Abstract][Full Text] [Related]
13. Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model. Foronjy RF; Sun J; Lemaitre V; D'Armiento JM Hypertens Res; 2008 Apr; 31(4):725-35. PubMed ID: 18633185 [TBL] [Abstract][Full Text] [Related]
14. Cardiac fibrosis in the ageing heart: Contributors and mechanisms. Lu L; Guo J; Hua Y; Huang K; Magaye R; Cornell J; Kelly DJ; Reid C; Liew D; Zhou Y; Chen A; Xiao W; Fu Q; Wang BH Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():55-63. PubMed ID: 28316086 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of autophagy inhibits the conversion of cardiac fibroblasts to cardiac myofibroblasts. Gupta SS; Zeglinski MR; Rattan SG; Landry NM; Ghavami S; Wigle JT; Klonisch T; Halayko AJ; Dixon IM Oncotarget; 2016 Nov; 7(48):78516-78531. PubMed ID: 27705938 [TBL] [Abstract][Full Text] [Related]
16. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Gao S; Long CL; Wang RH; Wang H Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of myocardial fibrosis in hypertensive heart disease. Díez J Circ J; 2008; 72 Suppl A():A8-12. PubMed ID: 18772529 [TBL] [Abstract][Full Text] [Related]
18. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Paulus WJ; Tschöpe C J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677 [TBL] [Abstract][Full Text] [Related]
19. Functional brown adipose tissue limits cardiomyocyte injury and adverse remodeling in catecholamine-induced cardiomyopathy. Thoonen R; Ernande L; Cheng J; Nagasaka Y; Yao V; Miranda-Bezerra A; Chen C; Chao W; Panagia M; Sosnovik DE; Puppala D; Armoundas AA; Hindle A; Bloch KD; Buys ES; Scherrer-Crosbie M J Mol Cell Cardiol; 2015 Jul; 84():202-11. PubMed ID: 25968336 [TBL] [Abstract][Full Text] [Related]